Pregnancy Outcomes Following Exposure to Quinolone Antibiotics – a Systematic-Review and Meta-Analysis

  • Aviva Ziv
  • Reem Masarwa
  • Amichai Perlman
  • Danny Ziv
  • Ilan Matok
Expert Review Theme: The Use of Therapeutics in Pregnancy and Lactation
  • 61 Downloads
Part of the following topical collections:
  1. The Use of Therapeutics in Pregnancy and Lactation

Abstract

Purpose

Quinolones, and the fluoroquinolones subgroup, are a class of antibiotics commonly used for the treatment of a wide variety of infections. However, their safety profile in pregnant women is controversial. The association between fluoroquinolones and arthropathy was primarily described in immature animals, and only rarely in humans, yet it has led to the restricted use of quinolones during pregnancy. We aimed to assess their safety during pregnancy.

Methods

A systematic review and meta-analysis assessing the safety of quinolone exposure during any time of pregnancy, and during first trimester alone, was performed. The systematic review was performed using MEDLINE and EMBASE, and followed the PRISMA guidelines. Pooled effect sizes with corresponding 95% confidence intervals (CI) were calculated using random effects models, comparing fetal outcomes of quinolone exposed and non-exposed pregnancies. Only cohort and case control studies were included in the meta-analysis.

Result

Twelve studies met the inclusion criteria. Exposure to quinolones during first trimester was not associated with an increased risk for birth defects (pooled odds ratio (OR) = 0.89, 95% CI 0.72–1.09, I2 = 0%), stillbirth (OR = 1.32, 95% CI 0.33–5.34, I2 = 16%), preterm birth (OR = 1.10, 95% CI 0.83–1.48, I2 = 41%) and low birth weight (OR = 1.29, 95% CI 0.54–3.12, I2 = 67%).

Conclusion

The use of quinolones during the first-trimester of pregnancy was not associated with an increased risk of birth defects, stillbirths, preterm births or low birth weight.

Study Registry

PROSPERO CRD42017060573.

Key Words

birth defects congenital abnormalities congenital malformations fluoroquinolones pregnancy outcomes pregnancy 

Supplementary material

11095_2018_2383_MOESM1_ESM.docx (19 kb)
ESM 1 (DOCX 19.2 kb)
11095_2018_2383_MOESM2_ESM.docx (38 kb)
ESM 2 (DOCX 37.9 kb)
11095_2018_2383_MOESM3_ESM.docx (33 kb)
ESM 3 (DOCX 32.9 kb)
11095_2018_2383_MOESM4_ESM.docx (33 kb)
ESM 4 (DOCX 33.1 kb)
11095_2018_2383_MOESM5_ESM.docx (33 kb)
ESM 5 (DOCX 32.6 kb)
11095_2018_2383_MOESM6_ESM.docx (261 kb)
ESM 6 (DOCX 260 kb)
11095_2018_2383_MOESM7_ESM.docx (27 kb)
ESM 7 (DOCX 27.0 kb)
11095_2018_2383_MOESM8_ESM.docx (39 kb)
ESM 8 (DOCX 38.7 kb)
11095_2018_2383_MOESM9_ESM.docx (27 kb)
ESM 9 (DOCX 27.2 kb)
11095_2018_2383_MOESM10_ESM.docx (96 kb)
ESM 10 (DOCX 95.9 kb)
11095_2018_2383_MOESM11_ESM.docx (22 kb)
ESM 11 (DOCX 22.1 kb)

References

  1. 1.
    Phillips I, King A, Shannon K. The Quinolones. The Quinolones, Elsevier; 2000. Available from: http://www.sciencedirect.com/science/article/pii/B9780120595174500040. cited 2016 Feb 19.
  2. 2.
    Oliphant CM, Quinolones GGM. A comprehensive review. Am Fam Physician. 2002;65:455–64.PubMedGoogle Scholar
  3. 3.
    Melhus Å, Apelqvist J, Larsson J, Eneroth M. Levofloxacin-associated Achilles tendon rupture and tendinopathy. Scand J Infect Dis. 2003;35:768–70.CrossRefPubMedGoogle Scholar
  4. 4.
    Alfaham M, Holt ME, Googchild MC. Arthropathy in a patient with cystic fibrosis taking ciprofloxacin. Br Med J. 1986;295:699.CrossRefGoogle Scholar
  5. 5.
    Samuelson WM, Roy A, Pleasants MSW. Arthropathy secondary to ciprofloxacin in an adult cystic fibrosis patient. Ann Pharmacother. 1993;27(3):302–3.CrossRefPubMedGoogle Scholar
  6. 6.
    Choi SH, Kim EY, Kim YJ. Systemic use of fluoroquinolone in children. Korean J Pediatr. 2013;56:196–201.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child. 2011;96:874–80.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Schaad UB, Wedgwood J. Lack of quinolone-induced arthropathy in children. J Antimicrob Chemother. 1992;30:414–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Kaguelidou F, Turner MA, Choonara I, Jacqz-Aigrain E. Ciprofloxacin Use in Neonates. Pediatr Infect Dis J. 2011;30:e29–37. Available from: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00006454-201102000-00032. cited 2018 Jan 10.
  10. 10.
    Research C for DE and. Bioterrorism and Drug Preparedness - CIPRO (Ciprofloxacin) Use by Pregnant and Lactating Women. Center for Drug Evaluation and Research; Available from: https://www.fda.gov/drugs/emergencypreparedness/bioterrorismanddrugpreparedness/ucm130712.htm. cited 2017 Jul 19.
  11. 11.
    Padberg S, Wacker E, Meister R, Panse M, Weber-schoendorfer C, Oppermann M. Observational cohort study of pregnancy outcome after first- trimester exposure to fluoroquinolones. Antimicrob Agents Chemother. 2014;58(8):4392–8.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Loebstein R, Addis A, Ho E, Andreou R, Sage S, Donnenfeld AE, et al. Pregnancy Outcome Following Gestational Exposure to Fluoroquinolones: a Multicenter Prospective Controlled Study. 1998;42:1336–9.Google Scholar
  13. 13.
    Pundir J, Coomarasamy A. Infections in pregnancy. In obstetrics: evidence-based algorithms. Cambridge: Cambridge University Press; 2016.CrossRefGoogle Scholar
  14. 14.
    Oral Health Care During Pregnancy Expert Workgroup. Oral Health Care During Pregnancy: A national consensus statement.Washington, DC: National Maternal and Child Oral Health Resource Center. 2012.Google Scholar
  15. 15.
    Adam HJ, Hoban DJ, Gin AS, Zhanel GG. Association between fluoroquinolone usage and a dramatic rise in ciprofloxacin-resistant Streptococcus pneumoniae in Canada, 1997-2006. Int J Antimicrob Agents. 2009;34:82–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Linder JA, Huang ES, Steinman MA, Gonzales R, Stafford RS. Fluoroquinolone prescribing in the United States: 1995 to 2002. Am J Med. 2005;118:259–68.CrossRefPubMedGoogle Scholar
  17. 17.
    Research C for DE and. Drug Safety and Availability - FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Center for Drug Evaluation and Research; Available from: https://www.fda.gov/Drugs/DrugSafety/ucm511530.htm. cited 2018 Jan 26.
  18. 18.
    Rauch F, Schoenau E. Skeletal development in premature infants: a review of bone physiology beyond nutritional aspects. Arch Dis Child Fetal Neonatal Ed. 2002;86:F82–5.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Moniz MH, Gavin LE, Dalton VK. Performance measures for contraceptive care. Obstet Gynecol. 2017;130:1. Available from: http://insights.ovid.com/crossref?an=00006250-900000000-98278 Google Scholar
  20. 20.
    Moher D, Liberati A, Tetzlaff J, Altman DG, Altman D, Antes G, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.  https://doi.org/10.1371/journal.pmed.1000097
  21. 21.
    Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Ottawa Hosp Res Inst. http://www.ohri.ca/programs/clinical_epidemiology/nosgen.pdf. cited 2017 Mar 10.
  22. 22.
    Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.CrossRefPubMedGoogle Scholar
  23. 23.
    Dudás I, Puhó E, Czeizel AE. Population-based case-control study of oxoline acid use during pregnancy for birth outcomes. Congenit Anom (Kyoto). 2006;46:39–42.CrossRefGoogle Scholar
  24. 24.
    Crider K, Cleves M, Reefhuis J, Berry R, Hobbs C, Hu D. Antibacterial medication use during pregnancy and risk of birth defects. Arch Pediatr Adolesc Med. 2009;163:978–85.CrossRefPubMedGoogle Scholar
  25. 25.
    Matok I, Koren G, Gorodischer R, Levy A. Exposure to Quinolones during Pregnancy: Lack of Association with an Increased Risk for Birth Defects and Other Adverse Pregnancy Outcomes. Pharmacoepidemiol Drug Saf. 2010;19:S245. Available from: https://insights.ovid.com/pharmacoepidemiology-drug-safety/pads/2010/08/001/578-exposure-quinolones-during-pregnancy-lack/578/01445491. cited 2017 Jul 19.
  26. 26.
    Watanabe O, Nakajima K, Ishii M, Yakuwa N, Murashima A. Pregnancy outcome after first trimester exposure to quinolones. Birth Defects Res Part A - Clin Mol Teratol. 2013;97(5):367. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&CSC=Y&NEWS=N&PAGE=fulltext&D=emed15&AN=71430619 Google Scholar
  27. 27.
    Larsen H, Nielsen GL, Schønheyder HC, Olesen C, Sørensen HT. Birth outcome following maternal use of fluoroquinolones. Int J Antimicrob Agents. 2001;18:259–262.CrossRefPubMedGoogle Scholar
  28. 28.
    Wogelius P, Nørgaard M, Gislum M, Pedersen L, Schønheyder HC, Toft H. Further analysis of the risk of adverse birth outcome after maternal use of fluoroquinolones. 2005;26:323–326.Google Scholar
  29. 29.
    Wilton LV, Pearce GL, Mann RD. A comparison of ciprofloxacin, norfloxacin, ofloxacin, azithromycin and cefixime examined by observational cohort studies. Br J Clin Pharmacol Pharmacol. 1996;41:277–284.CrossRefGoogle Scholar
  30. 30.
    Cooper WO, Hernandez-diaz S, Arbogast PG, Dudley JA, Dyer SM, Gideon PS, et al. Antibiotics potentially used in response to bioterrorism and the risk of major congenital malformations. Paediatr Perinat Epidemiol. 2008;23(1):18–28.Google Scholar
  31. 31.
    Berkovitch M, Pastuszak A, Gazarian M, Lewis M. Koren G. Safety of the new quinolones in pregnancy. 1994;84:535. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=cin20&AN=107299379 Google Scholar
  32. 32.
    Muanda FT, Sheehy O, Bérard A. Use of antibiotics during pregnancy and risk of spontaneous abortion. Can Med Assoc J. 2017;189:E625–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28461374. cited 2017 Jul 19.
  33. 33.
    Regan L, Rai R. Epidemiology and the medical causes of miscarriage. Bailliere’s Best Pract Res Clin Obstet Gynaecol. 2000;14:839–54.CrossRefGoogle Scholar
  34. 34.
    Nahum GG, Uhl K, Kennedy DL. Antibiotic use in pregnancy and lactation: what is and is not known about teratogenic and toxic risks. Obstet Gynecol. 2006;107:1120–38. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16648419 CrossRefPubMedGoogle Scholar
  35. 35.
    Wood AJJ, Koren G, Pastuszak A, Ito S. Drugs in Pregnancy. N Engl J Med. Massachusetts Medical Society; 1998;338:1128–37. Available from: http://www.nejm.org, doi:  https://doi.org/10.1056/NEJM199804163381607. cited 2017 Jul 19.
  36. 36.
    Sendzik J, Lode H, Stahlmann R. Quinolone-induced arthropathy: an update focusing on new mechanistic and clinical data. Int J Antimicrob Agents. 2009;33:194–200.CrossRefPubMedGoogle Scholar
  37. 37.
    Ingham B, Brentnall DW, Dale A, Mcfadzean JA. Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acids. Toxiciology Lett. 1977;1:21–6.CrossRefGoogle Scholar
  38. 38.
    Schluter G. Ciprofloxacin: Toxicologic evaluation of additional safety data. Am J Med. 1989;87:S37–9.CrossRefGoogle Scholar
  39. 39.
    Ozyuncu O, Nemutlu E, Katlan D, Kir S, Beksac MS. International journal of antimicrobial agents maternal and fetal blood levels of moxifloxacin, levofloxacin, cefepime and cefoperazone. Int J Antimicrob Agents Elsevier BV 2010;36:175–178. Available from: https:doi.org/ https://doi.org/10.1016/j.ijantimicag.2010.03.011
  40. 40.
    Giamarellou[RM1] H, Kolokmhas E. Pharmacokinetics of three newer quinolones in pregnant and lactating women. Am J Med. 1989;87:49–51.Google Scholar
  41. 41.
    Polachek H, Holcberg G, Sapir G, Tsadkin-tamir M. Transfer of ciprofloxacin, ofloxacin and levofloxacin across the perfused human placenta in vitro. Eur J Obstet Gynecol Reprod Biol. 2005;122:61–5.CrossRefPubMedGoogle Scholar
  42. 42.
    Bar-Oz B, Moretti ME, Boskovic R, O’Brien L, Koren G. The safety of quinolones-a meta-analysis of pregnancy outcomes. Eur J Obstet Gynecol Reprod Biol. 2009;143:75–8.CrossRefPubMedGoogle Scholar
  43. 43.
    Yefet E, Salim R, Chazan B, Akel H, Romano S, Nachum Z. The Safety of Quinolones in Pregnancy. Obstet Gynecol Surv. 2014;69:681–94. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25409160. cited 2017 Jul 19.
  44. 44.
    Mazor-Dray E, Levy A, Schlaeffer F, Sheiner E. Maternal urinary tract infection: is it independently associated with adverse pregnancy outcome? J Matern Neonatal Med. Taylor & Francis; 2009;22:124–8. Available from: http://www.tandfonline.com, doi:  https://doi.org/10.1080/14767050802488246. cited 2017 Nov 30.

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Pharmacoepidemiology Research Unit, Division of Clinical Pharmacy Institute for Drug Research, School of PharmacyThe Hebrew University of JerusalemJerusalemIsrael

Personalised recommendations